Literature DB >> 11934229

Prevention of autoimmune insulitis by delivery of interleukin-4 plasmid using a soluble and biodegradable polymeric carrier.

Minhyung Lee1, Jae Joon Koh, Sang-Oh Han, Kyung Soo Ko, Sung Wan Ki.   

Abstract

PURPOSE: We delivered interleukin-4 (IL-4) plasmid (pCAGGS-IL-4) using the biodegradable polymer, poly[alpha-(4-aminobutyl)-L-glycolic acid] (PAGA), to prevent autoimmune insulitis in NOD mice.
METHODS: The pCAGGS-IL-4/PAGA complex was transfected to 293T cells. The expression level of IL-4 was measured by ELISA. The pCAGGS IL-4/PAGA complex was injected once to NOD mice intravenously at the age of 4 weeks. RT-PCR was performed to evaluate the level of the IL-4 mRNA in the liver. At 6 weeks after the injection, the grade of insulitis of the mice was evaluated by double blind methods.
RESULTS: In vitro transfecton assays showed that PAGA enhanced the expression of IL-4 in 293T cells. RT-PCR of the liver showed that IL-4 was expressed highest in the complex injected group. In the plasmid/PAGA complex injected group, the prevalence of severe insulitis in NOD mice was markedly improved, suggesting that PAGA enhanced the delivery of IL-4 plasmid.
CONCLUSION: The pCAGGS-IL-4/PAGA complex is an effective system to prevent autoimmune insulitis in NOD mice and applicable for the prevention of autoimmune diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11934229     DOI: 10.1023/a:1014478515005

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  22 in total

Review 1.  Development of biomaterials for gene therapy.

Authors:  S Han; R I Mahato; Y K Sung; S W Kim
Journal:  Mol Ther       Date:  2000-10       Impact factor: 11.454

2.  Mechanism underlying counterregulation of autoimmune diabetes by IL-4.

Authors:  R Mueller; L M Bradley; T Krahl; N Sarvetnick
Journal:  Immunity       Date:  1997-09       Impact factor: 31.745

3.  Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes.

Authors:  S Trembleau; G Penna; S Gregori; M K Gately; L Adorini
Journal:  Eur J Immunol       Date:  1997-09       Impact factor: 5.532

Review 4.  The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD.

Authors:  T L Delovitch; B Singh
Journal:  Immunity       Date:  1997-12       Impact factor: 31.745

Review 5.  Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases.

Authors:  R S Liblau; S M Singer; H O McDevitt
Journal:  Immunol Today       Date:  1995-01

Review 6.  Gene therapy of autoimmune diseases with vectors encoding regulatory cytokines or inflammatory cytokine inhibitors.

Authors:  G J Prud'homme
Journal:  J Gene Med       Date:  2000 Jul-Aug       Impact factor: 4.565

7.  Immunotherapy of spontaneous type 1 diabetes in nonobese diabetic mice by systemic interleukin-4 treatment employing adenovirus vector-mediated gene transfer.

Authors:  M J Cameron; G A Arreaza; L Waldhauser; J Gauldie; T L Delovitch
Journal:  Gene Ther       Date:  2000-11       Impact factor: 5.250

8.  Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes.

Authors:  B Wang; I André; A Gonzalez; J D Katz; M Aguet; C Benoist; D Mathis
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

9.  Systemic delivery of interleukin 10 by intramuscular injection of expression plasmid DNA prevents autoimmune diabetes in nonobese diabetic mice.

Authors:  Y Nitta; F Tashiro; M Tokui; A Shimada; I Takei; K Tabayashi; J Miyazaki
Journal:  Hum Gene Ther       Date:  1998-08-10       Impact factor: 5.695

10.  T helper cell subsets in insulin-dependent diabetes.

Authors:  J D Katz; C Benoist; D Mathis
Journal:  Science       Date:  1995-05-26       Impact factor: 47.728

View more
  7 in total

1.  "Persistence of Diabetes" - Why Has Research into Type 1 Diabetes not Made Significant Advances?

Authors:  Charles Sia; Michael Weinem
Journal:  Rev Diabet Stud       Date:  2007-02-10

2.  Effect of Lactobacillus casei on the Production of Pro-Inflammatory Markers in Streptozotocin-Induced Diabetic Rats.

Authors:  A Zarfeshani; H Khaza'ai; R Mohd Ali; Z Hambali; K W J Wahle; M S A Mutalib
Journal:  Probiotics Antimicrob Proteins       Date:  2011-12       Impact factor: 4.609

3.  AAV8-mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice.

Authors:  Khaja K Rehman; Massimo Trucco; Zhong Wang; Xiao Xiao; Paul D Robbins
Journal:  Mol Ther       Date:  2008-06-17       Impact factor: 11.454

Review 4.  Regulation of type 1 diabetes, tuberculosis, and asthma by parasites.

Authors:  Zhugong Liu; Qian Liu; David Bleich; Padmini Salgame; William C Gause
Journal:  J Mol Med (Berl)       Date:  2009-10-21       Impact factor: 4.599

5.  Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice.

Authors:  Rémi J Creusot; Shahriar S Yaghoubi; Keiichi Kodama; Demi N Dang; Vu H Dang; Karine Breckpot; Kris Thielemans; Sanjiv S Gambhir; C Garrison Fathman
Journal:  Clin Immunol       Date:  2008-03-12       Impact factor: 3.969

6.  Interleukin-4-expressing plasmid DNA inhibits reovirus type-2-triggered autoimmune insulitis in DBA/1 J suckling mice.

Authors:  T Hayashi; Y Yasutomi; K Hasegawa; Y Sasaki; T Onodera
Journal:  Int J Exp Pathol       Date:  2003-04       Impact factor: 1.925

Review 7.  Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy.

Authors:  Toshiharu Hayashi
Journal:  J Biomed Biotechnol       Date:  2010-08-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.